| pubmed-article:7094201 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7094201 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:7094201 | lifeskim:mentions | umls-concept:C0678222 | lld:lifeskim |
| pubmed-article:7094201 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:7094201 | lifeskim:mentions | umls-concept:C1518174 | lld:lifeskim |
| pubmed-article:7094201 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:7094201 | lifeskim:mentions | umls-concept:C1709059 | lld:lifeskim |
| pubmed-article:7094201 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7094201 | pubmed:dateCreated | 1982-9-10 | lld:pubmed |
| pubmed-article:7094201 | pubmed:abstractText | We have previously demonstrated a highly significant relationship (P less than 0.0001) between the incorporation of 5-fluorouracil (5-FU) into total cellular RNA and loss of clonogenic survival of the human MCF-7 breast carcinoma cell line. The present studies explore the applicability of this relationship to MCF-7 cells exposed to 5-FU and modulating agents such as PALA, MTX, and MMPR. PALA treatment produces a minimal increase in the absolute amount of 5-FU incorporated into total cellular RNA, but it results in a three-fold enhancement of the [3H]FU/32P ratio, which measures 5-FU misincorporation into newly synthesized RNA. MTX and MMPR increase intracellular PRPP levels up to four-fold; nevertheless these agents result in only minimal increases in absolute (5-FU)RNA formation. In contrast, the relative incorporation of 5-FU into newly synthesized RNA of MTX- or MMPR-treated cells is increased 2.5-fold. The combination of PALA/MMPR results in a two-fold absolute increase in (5-FU)RNA formation and a nine-fold enhancement of the [3H]FU/32P ratio. Combinations of modulating agents with 5-FU result in more than additive decreases in MCF-7 clonogenic survival. The relationship between 5-FU incorporation into RNA and loss of clonogenic survival was highly significant (P less than 0.0002) when corrected for newly synthesized RNA, while the correlation with absolute amounts of (5-FU)RNA formation was less significant (P less than 0.05). These studies demonstrate that the relationship previously established between (5-FU)RNA formation and loss of clonogenic survival should be corrected for the amount of newly synthesized RNA when 5-FU is combined with modulating agents that alter rates of RNA synthesis. | lld:pubmed |
| pubmed-article:7094201 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7094201 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7094201 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7094201 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7094201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7094201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7094201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7094201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7094201 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7094201 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:7094201 | pubmed:author | pubmed-author:EganE MEM | lld:pubmed |
| pubmed-article:7094201 | pubmed:author | pubmed-author:KufeD WDW | lld:pubmed |
| pubmed-article:7094201 | pubmed:author | pubmed-author:MajorP PPP | lld:pubmed |
| pubmed-article:7094201 | pubmed:author | pubmed-author:SargentLL | lld:pubmed |
| pubmed-article:7094201 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7094201 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:7094201 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7094201 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7094201 | pubmed:pagination | 87-91 | lld:pubmed |
| pubmed-article:7094201 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7094201 | pubmed:meshHeading | pubmed-meshheading:7094201-... | lld:pubmed |
| pubmed-article:7094201 | pubmed:meshHeading | pubmed-meshheading:7094201-... | lld:pubmed |
| pubmed-article:7094201 | pubmed:meshHeading | pubmed-meshheading:7094201-... | lld:pubmed |
| pubmed-article:7094201 | pubmed:meshHeading | pubmed-meshheading:7094201-... | lld:pubmed |
| pubmed-article:7094201 | pubmed:meshHeading | pubmed-meshheading:7094201-... | lld:pubmed |
| pubmed-article:7094201 | pubmed:meshHeading | pubmed-meshheading:7094201-... | lld:pubmed |
| pubmed-article:7094201 | pubmed:meshHeading | pubmed-meshheading:7094201-... | lld:pubmed |
| pubmed-article:7094201 | pubmed:meshHeading | pubmed-meshheading:7094201-... | lld:pubmed |
| pubmed-article:7094201 | pubmed:year | 1982 | lld:pubmed |
| pubmed-article:7094201 | pubmed:articleTitle | Modulation of 5-FU metabolism in human MCF-7 breast carcinoma cells. | lld:pubmed |
| pubmed-article:7094201 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7094201 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7094201 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7094201 | lld:pubmed |
